News Immunocore Holdings plc

Equities

IMCR

US45258D1054

Real-time Estimate Cboe BZX Other stock markets 08:49:04 27/06/2024 pm IST			5-day change	1st Jan Change
33.94 ^USD	-0.09%		-3.42%	-50.35%

18/06	Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	MT
18/06	Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunocore : Corporate Presentation – June 2024	19/06	PU
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06	MT
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma	18/06	GL
Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma	18/06	CI
Immunocore : Earnings Release Q3 2023	14/06	PU
Immunocore : Earnings Release FY 2022	14/06	PU
Immunocore : Earnings Release Q1 2021	14/06	PU
Immunocore : Earnings Release Q1 2024	14/06	PU
Immunocore : Earnings Release Q2 2023	14/06	PU
Immunocore : Earnings Release Q1 2023	14/06	PU
Immunocore : Earnings Release FY 2021	14/06	PU
Immunocore : Earnings Release FY 2023	14/06	PU
Immunocore : Earnings Release Q3 2022	14/06	PU
Immunocore : Earnings Release Q2 2022	14/06	PU
Immunocore : Earnings Release Q1 2022	14/06	PU
Immunocore : Earnings Release Q3 2021	14/06	PU
Immunocore : Earnings Release Q2 2021	14/06	PU
Immunocore : Earnings Release FY 2020	14/06	PU
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	01/06	AQ
Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response	01/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immunocore Holdings plc

Equities

IMCR

US45258D1054

Summary

Filters